This publication is a positive scientific milestone but does not change the binary risk of the Phase 3 ProstACT Global trial. Monitor for enrollment updates and interim data from the Phase 3 study, which will be the primary catalyst for TLX591-Tx's valuation.
Drugs in focus
TLX drug pipeline →TLX591-Tx
● Neutral Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- Likely 2028+ (Phase 3 Part 2 enrollment underway, followed by event-driven rPFS readout, then regulatory filing)
- Next catalyst
- None dated
What to watchWatch for enrollment completion updates on ProstACT Global Part 2 and any interim rPFS data. The stock is heavily influenced by Illuccix/Gozellix revenue execution, so TLX591-Tx is a pipeline upside option, not the core thesis today. Near-term catalysts center on Telix's imaging franchise (Pixclara PDUFA) rather than this therapeutic.
- ▲ Gozellix 3/10 Approved (FDA, March 21, 2025 — NDA 219592, 505(b)(2)) Named in filing
- ◆ ITM-11 4/10 Phase 3 (completed)
- ● Zircaix 4/10 Phase 3 (ZIRCON) completed; BLA under FDA review
- ● TLX101-Tx 3/10 Phase 3 (pivotal, just initiated); Phase 1 safety stage complete
- All TLX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 22 $10.32entry
- T+1 · 4mo ago +1.84%α +3.08% · $10.51
- T+5 · 4mo ago −2.13%α +0.27% · $10.10
- T+20 · 3mo ago +17.44%α +14.55% · $12.12
- T+60 · 5w ago +2.42%α −0.84% · $10.57
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Telix announced peer-reviewed publication of ProstACT SELECT Phase 1 results in Cancers, confirming that 68Ga-PSMA-PET imaging can select patients for TLX591-Tx therapy. The data show a median radiographic progression-free survival of 8.8 months in evaluable patients, a manageable safety profile, and prolonged tumor retention. This is a positive scientific validation for TLX591-Tx's patient-selection strategy and supports the ongoing Phase 3 ProstACT Global trial, but does not change the binary regulatory or commercial outlook for the asset.
Key Facts
- ProstACT SELECT Phase 1 results published in peer-reviewed journal Cancers.
- Median radiographic progression-free survival (rPFS) of 8.8 months reported in evaluable patients.
- TLX591-Tx demonstrated manageable safety profile and prolonged tumor retention with low salivary gland irradiation.
- Publication supports patient-selection strategy for ongoing Phase 3 ProstACT Global trial in mCRPC.
Financial Impact
No financial figures disclosed; publication is scientific validation only.
Risk Factors
- Phase 3 ProstACT Global trial may fail to replicate efficacy or safety results.
- TLX591-Tx has not received marketing authorization in any jurisdiction; regulatory path is uncertain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3330996 |
Track record
27 reports on TLX
9 of 20 bullish or bearish reports moved the stock their way by T+1. Best: +29.26% at T+20 after the Jun 1, 2026 report. 18 of 20 went positive at some point.
Filters
- Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
- Oct 20, 202627d ago 6-K Neutral 4/10 No price data
- Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
- Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
- Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 14, 20269w ago 6-K Bullish 8/10 Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
- Sep 14, 20269w ago Press Release Bullish 8/10 Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
- Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
- Sep 1, 202610w ago Press Release Bullish 6/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers